Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taho PharmaceuticalsROCO:6467 -4.22%35 Market Cap is NT$5,944.12 Mil as of Jul. 19, 2026. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Taho Pharmaceuticals ranks worse than 52.69% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Taho Pharmaceuticals's share price for the quarter that ended in Dec. 2025 was NT$111. Taho Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 52.36 Mil. Therefore, Taho Pharmaceuticals's market cap for the quarter that ended in Dec. 2025 was NT$5,811.52 Mil.
Taho Pharmaceuticals's quarterly market cap
increased
from Dec. 2024 (NT$2,271.38 Mil) to Jun. 2025 (NT$2,715.38 Mil) and
increased
from Jun. 2025 (NT$2,715.38 Mil) to Dec. 2025 (NT$5,811.52 Mil).
Taho Pharmaceuticals's annual market cap
increased
from Dec. 2023 (NT$97.30 Mil) to Dec. 2024 (NT$2,271.38 Mil) and
increased
from Dec. 2024 (NT$2,271.38 Mil) to Dec. 2025 (NT$5,811.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Taho Pharmaceuticals's Enterprise Value for Today is NT$5,565.46 Mil.
Taho Pharmaceuticals (ROCO:6467) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Taho Pharmaceuticals Market Cap Related Terms
Taho Pharmaceuticals Market Cap Historical Data
* Premium members only.
The historical data trend for Taho Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taho Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Taho Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Taho Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taho Pharmaceuticals (ROCO:6467) has a Market Cap of NT$5,944.12 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taho Pharmaceuticals and its competitors. According to the industry distribution chart, Taho Pharmaceuticals ranks #539 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Taho Pharmaceuticals' Market Cap too high?
Taho Pharmaceuticals' current Market Cap is NT$5,944.12 Mil. Based on the distribution chart, Taho Pharmaceuticals ranks #539 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taho Pharmaceuticals ranks #539 out of 1023 companies for Market Cap. This places Taho Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 216.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 216.46, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taho Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 216.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current Market Cap is NT$5,944.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Market Cap of NT$5,944.12 Mil. The current Market Cap is NT$5,944.12 Mil. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Market Cap is NT$5,944.12 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score
Get the complete analysis for ROCO:6467
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6467 has been successfully added to your 
